Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 23, 2025Future Oncology

PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDiao KongYTYujuan TangYZYongjie Zhou

Discussion

Loading...

Member takes

Overview

Phase II trial shows major pathological response in resectable HCC using TACE and lenvatinib, indicating potential for perioperative therapies.

Key Points

  • Major pathological response achieved in patients with high-risk hepatocellular carcinoma using TACE and lenvatinib.
  • Primary endpoint focused on major pathological response rate of the treatment strategy applied.
  • Trial assessed both neoadjuvant and adjuvant administration of therapies in a single arm setup.
  • Results may highlight new pathways for improving outcomes in early-stage liver cancer post-surgery.

Cite This Study

Kong et al. (2025) studied this question.

synapsesocial.com/papers/68fa32a40df2e6cd2f742256https://doi.org/10.1080/14796694.2025.2577625
View Full Paper
Ask AI
Bookmark
Share